Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response

Glioblastoma multiforme (GBM) is the most common and most aggressive type of primary brain cancer. Since median overall survival with multimodal standard therapy is only 15 months, there is a clear need for additional effective and long-lasting treatments. Dendritic cell (DC) vaccination is an exper...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Dejaegher, Joost, Van Gool, Stefaan, De Vleeschouwer, Steven
Aineistotyyppi: Online Artikkeli Teksti
Kieli:English
Julkaistu: Dove Medical Press 2014
Aiheet:
Review
Linkit:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918234/
https://www.ncbi.nlm.nih.gov/pubmed/27471700
http://dx.doi.org/10.2147/ITT.S40121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918234/
https://www.ncbi.nlm.nih.gov/pubmed/27471700
http://dx.doi.org/10.2147/ITT.S40121

Samankaltaisia teoksia